Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02181491 · ClinicalTrials.gov registry record · NA
PET Imaging in Cocaine Self Administration
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02181491 is a NA study that has completed, run by Yale University. The registered enrollment target is 30 participants.
The verdict
NCT02181491, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
There has been recent interest in the role of the 5-HT1B receptor as a possible modulating factor in cocaine dependence, certainly in preclinical models. The Yale Positron Emission Tomography (PET) Center has developed a novel 5-HT1B receptor antagonist radioligand, \[11C\]-P943, which has been validated in human studies. We hypothesize that the 5-HT1B receptor plays a key role in cocaine dependence. The long term goal of this project would be to study pharmacological manipulation of the 5-HT1B receptor as a potential molecular target for cocaine dependence.
Interventions
- OTHER [11C]-P943
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-07 |
| Est. Completion | 2019-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02181491
The ClinicalTrials.gov registry entry for NCT02181491 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [11C]-P943 is the first listed.
NCT02181491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02181491 about?
NCT02181491 is a clinical study titled "PET Imaging in Cocaine Self Administration". There has been recent interest in the role of the 5-HT1B receptor as a possible modulating factor in cocaine dependence, certainly in preclinical models. The Yale Positron Emission Tomography (PET) Center has developed a novel 5-HT1B receptor antagonist radioligand, \[11C\]-P943, which has been vali...
What is the current status of trial NCT02181491?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2014-07. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02181491?
The interventions under investigation include: [11C]-P943 (OTHER).
Who is sponsoring clinical trial NCT02181491?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.